InvestorsHub Logo
icon url

zugisland

11/20/19 12:33 PM

#228792 RE: ggwpq #228790

By all accounts i think anyone with ACST should sell and Buy AMRN on this big dip...the near term upside is so much greater ! And thus totally fade this analyst reach of a call...
icon url

KCSVEN

11/20/19 12:35 PM

#228794 RE: ggwpq #228790

I wonder what analyses he did about off label use? We all know about the expensive cost off label and the doctors not wanting to go through hoops to prescribe. I'm sure he spent a ton of time on this analyses.

"omega-3 generics, dietary supplements, and foreseeable competition,” he wrote."

Ummm, What?
1-the population that the label will be for can get the drug cheaper through insurance in the future than they could even by OTC, if you are not able to get it because you don't qualify you may take OTC but nobody eligible for Vascepa would do OTC, they'd get the purified real thing.

2-There are no generics in the main population Vascepa will be prescribed for

3-There is no foreseeable competition

What a loser!
icon url

marzan

11/20/19 12:38 PM

#228795 RE: ggwpq #228790

Link please. TIA
icon url

biotechtrader2020

11/20/19 1:34 PM

#228824 RE: ggwpq #228790

Seriously? This is the PR they come up with?

If there are automated bots picking this up, the sentiment would come out as so negative.
Positive keywords: confident, signficantly grow
Negative keywords: products have failed, decade or more, considerable funding, not yet started, potentially show


Why not say
“We are confident in our ability to significantly grow Vascepa with an expanded label. Amarin's Vascepa is years ahead of competition and is currently the only product in this category to have shown meaningful benefits in outcomes study".

" “We are confident in our ability to significantly grow Vascepa with an expanded label,” the company said in a statement. “It’s also important to understand that many products have failed to demonstrate the positive results shown in REDUCE-IT and that it will take a decade or more and considerable funding for companies that have not yet started an outcomes study to potentially show benefit with products that have different mechanistic effects than Vascepa.”

icon url

rydad21

11/20/19 2:06 PM

#228848 RE: ggwpq #228790

Maybe the Oppy guy knows about an 8 for 1 stock split coming in the next 18 mos...